Tailored Information and Automated Reminding to Improve Medication Adherence in Spanish- and English-Speaking Elders Treated for Memory Impairment. by Ownby, Raymond L et al.
Tailored Information and Automated Reminding to Improve
Medication Adherence in Spanish- and English-Speaking Elders
Treated for Memory Impairment
Raymond L. Ownby, MD, PhD,
Nova Southeastern University, Fort Lauderdale, Florida, USA
Christopher Hertzog, PhD, and
Georgia Institute of Technology, Atlanta, Georgia, USA
Sara J. Czaja, PhD
University of Miami Miller School of Medicine, Miami, Florida, USA
Abstract
Medication adherence is recognized as an issue of critical importance within health care, as many
patients do not take their medications as prescribed. This study evaluated two interventions
targeted at improving adherence in elderly patients being treated for memory impairments.
Twenty-seven participants were randomly assigned to control (n = 11), automated reminding (n =
8), or tailored information conditions (n = 8). Medication adherence was evaluated with an
electronic pill bottle. Generalized estimating equation (GEE) models assessed the effects of the
interventions on electronically monitored medication adherence after controlling for covariates.
Results showed that individuals in both intervention groups had higher levels of medication
adherence than those in the control group. The presence of a caregiver was associated with
substantially higher levels of adherence. Verbal memory, but not general cognitive status,
predicted better adherence. Mood, health literacy, and executive functions were not associated
with adherence. Results thus suggest that both automated reminding and tailored information
interventions may improve medication adherence in elders, even among those with memory
impairments.
Keywords
adherence; Alzheimer’s disease; cognition; memory disorders
Medication adherence has been increasingly recognized as a significant factor in health
outcomes. A factor that may have been key in this increase are the related observations that
many patients do not take their medication as prescribed (Benner et al., 2002; Chapman,
Petrilla, Benner, Schwartz, & Tang, 2008) and that patients with better adherence have
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better health outcomes (Granger et al., 2005; Hays et al., 1994; Origasa, Yokoyama,
Matsuzaki, Saito, & Matsuzawa, 2010) including reduced risk of mortality (Simpson et al.,
2006). Several authors have argued that interventions to improve medication adherence
deserve serious attention (Cutler & Everett, 2010; Murray et al., 2007; Osterberg &
Blaschke, 2005; Simpson, 2006).
Adherence refers to the extent to which patients who are prescribed medications for a
disorder in fact take them at the appropriate time in the correct amount and manner (e.g.,
with or without food) as recommended by a clinician (Insel, Morrow, Brewer, & Figueredo,
2006). Studies have shown that patients may be inconsistent or irregular in taking
medications at levels that compromise the effectiveness of their treatment (Benner et al.,
2002; Grosset et al., 2009; Jackevicius, Mamdani, & Tu, 2002) Adherence may also decline
over time, a problem that can reduce the long-term effectiveness of medications prescribed
for chronic problems such as hypertension or hyperlipidemias (Chapman et al., 2008). The
reasons for declines in adherence over time are not clear, but may include an accumulation
of factors such as problems in paying for medications, ongoing experience with side effects,
and lack of evidence that medications have a positive effect (Chapman et al., 2008). Elderly
patients may be especially at high risk for medication nonadherence, especially if they have
memory impairments. The development of strategies to improve medication adherence is
thus critical to successful patient care and disease management.
Two strategies that have shown promise in promoting medication adherence include (a)
reminding techniques that prompt patients to take their medication at appropriate times,
addressing a common reason patients report for not taking their medications (Fulmer et al.,
1999; Osterberg & Blaschke, 2005) and (b) those that are designed to increase their internal
motivation to take their medication regularly. Reminding interventions have included:
directly observed therapy (in which a second person actually watches the person take their
medication), special pill bottles, automated telephone calls, and text messaging (Hardy et al.,
2011; Kirkland et al., 2002; Marquez et al., 2005; Pop-Eleches et al., 2011). Strategies to
affect patients’ motivation have focused on providing information about treatment, dealing
with barriers to adherence such as side effects or complex dosing regimens, and training in
adherence-related skills (Fisher et al., 2011).
A particularly effective strategy for communicating information with patients, in a way that
is likely to increase their motivation for adherence, has been through the use of tailored
information. While simple educational interventions improve patient adherence (Berrien,
Salazar, Reynolds, & McKay, 2004; Grosset & Grosset, 2007), information that is
individually tailored to a patients’ personal characteristics, interests, or needs may have a
significantly greater impact on their behavior. Information can, for example, be tailored to a
person’s gender, race, or ethnicity through related graphic elements such as pictures.
Information can also be tailored to an individual’s level of knowledge through the
administration of a pretest, or to his or her interests by administering a questionnaire that
assesses his or her interests in specific topics. Tailored information interventions have been
effective in promoting behavior change with respect to healthcare behaviors (Kreuter &
Wray, 2003).
Several reviews have documented the effectiveness of combinations of reminding and
motivational interventions in improving medication adherence (Conn et al., 2009; Haynes,
Ackloo, Sahota, McDonald, & Yao, 2008; van Eijken, Tsang, Wensing, de Smet, & Grol,
2003). Effective strategies to improve adherence, however, have often involved complex
and multifactorial interventions that include multiple components each of which may have
an impact (Lee, Grace, & Taylor, 2006). For example, the intervention used by Lee et al.
(2006) included not only individualized patient education but also special medication blister
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packs with medications grouped for each daily dose, and bi-monthly in-person follow-up
visits with a clinical pharmacist. The relative contribution of each element (education,
packaging, follow-up visits) is difficult to detect in this study. A clearer understanding of the
mechanisms through which interventions for adherence result in a positive impact on
outcomes requires some type of comparative effectiveness trial which compares distinct
interventions with known efficacy.
Computer-based applications may be useful as a method for implementing both types of
adherence-promoting interventions for patients by reducing costs associated with reminding
or motivation-enhancing interventions. While it is difficult or expensive to employ clinicians
in reminding patients to take medications or in providing tailored information, computers
can be employed to reduce the amount of clinician time required to implement the
intervention. An alternative to using clinicians to ensure that patients take their medications
appropriately, for example, has been to use technology to provide them with indirect
reminders. Reminders have been provided via special pill bottles, voice telephone calls, and
text messaging (Conn et al., 2009). It has been shown, for example, that computer-based
automation can be used to use send daily medication reminders to patients (Friedman et al.,
1996; Piette, Weinberger, & McPhee, 2000). A reminder message can be recorded and
played back at a predetermined time by an automated system. Once programmed, a
computer can dial the patient’s phone number, provide the reminder message, and request a
response in the form of a verbal response or a keypress on the telephone from whomever
answers the telephone (recognizing that the patient may not always answer the telephone).
The program can also redial a predetermined number of times if the telephone is not
answered, and provide records of the number of times the message is delivered.
Tailored information interventions delivered by computers have also been shown to be
effective in changing healthcare-related behaviors (Hawkins, Kreuter, Resnicow, Fishbein,
& Dijkstra, 2008; Kreuter & Wray, 2003). In fact, Johnson and colleagues (2006) showed
that a computer-based algorithm for information tailoring can improve medication
adherence. A review of interventions for medication adherence has shown that computer-
administered interventions were the most effective among various modes of delivery
(Cutrona et al., 2010). As with automated reminding, computer-based programs can reduce
the cost of tailored information interventions by automating the assessment and tailoring
process (Ross, 2008).
Given the incidence of memory impairment in older individuals and the relation of
increasing age to risk for Alzheimer’s disease, medication adherence in older adults may be
an especially important problem. Several studies have investigated medication adherence in
patients with memory impairment or Alzheimer’s disease. Memory problems are commonly
treated with cholinesterase inhibitors and for these patients adherence to a prescribed
regimen of therapy is essential to maintaining cognitive function. In spite of the importance
of sustained adherence to therapy, research suggest that these patients do not take their
medications regularly or persistently (Borah, Sacco, & Zarotsky, 2010; Gadzhanova,
Roughead, & Mackson, 2010; Gardette et al., 2010). Although no readily identifiable study
has investigated interventions to promote adherence in this population, one group has
reported on an intervention to improve medication adherence in patients treated for
Parkinson’s disease (Grosset & Grosset, 2007). Although both the patients with and
treatments for Alzheimer’s and Parkinson’s diseases are different in important ways,
affected patients are often similar with respect to age and comorbidities. Patients with
Parkinson’s disease may have cognitive impairments as well, and this study showed that
providing the patients information on the underlying neurochemistry of the disease and how
its pathology can be addressed through medications helped to improve their medication
adherence (Grosset & Grosset, 2007).
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A number of factors have been associated with medication adherence. Depression has
consistently been related to poorer medication adherence (Dimatteo, Lepper, & Croghan,
2000; Krousel-Wood et al., 2010) as have specific cognitive abilities (Hayes, Larimer,
Adami, & Kaye, 2009) such as memory or executive functions (Insel et al., 2006). Level of
health literacy has also been related to medication adherence (Gazmararian et al., 1999;
Kalichman, Ramachandran, & Catz, 1999).
In summary, interventions have been shown to improve patients’ medication adherence, but
effective interventions have usually included multiple components. This strategy makes it
difficult to determine which elements of the interventions are key contributors to their
success. Both reminding and information interventions may be effective in promoting
adherence, and computer-delivered interventions may be less costly than those that depend
on individual interventions. However, the efficacy of these strategies has not been
compared. Further, no readily identifiable study has investigated the impact of interventions
targeted at improving medication adherence in elders with memory problems or Alzheimer’s
disease. The purpose of this study was thus to evaluate the effect of two distinct
interventions on medication adherence in elders treated for memory problems while taking
factors such as depression and cognitive status into account. We hypothesized that both
approaches would significantly improve adherence but had no a priori hypothesis about
either method’s superiority.
METHOD
Participants were recruited from a university-affiliated memory disorders clinic in Miami
Beach, Florida, and had previously been evaluated by a multidisciplinary team and judged to
have clinically significant memory impairments. The clinic is one of several memory
disorder clinics supported by the state of Florida and draws patients from all of Miami-Dade
County. Approximately 50% of new patients are Spanish-speaking, and patients come from
a range of socioeconomic backgrounds. Patients in this clinic are typically older than 50
years of age, and in an earlier study we showed that they often have been prescribed
multiple medications for several problems as is typical of many older persons (Ownby,
Hertzog, Crocco, & Duara, 2006).
Participants were included in the study if they had been clinically judged to have a memory
problem and were being treated with one of the approved cholinesterase inhibitor
medications (donepezil, rivastigmine, or galantamine) or memantine and judged to be able
to give informed consent for their participation as described below. Some participants were
usually accompanied to the clinic by a spouse or other caregiver such as an adult child,
while others participated independently of other assistance. No participants were excluded
due to an inability to provide informed consent.
This study was completed under a protocol approved by the University of Miami Office of
Human Subjects Protection.
Treatment Conditions
Control—Participants assigned to the control condition participated in all study
assessments and regular monthly visits, but did not receive any additional information about
their condition, medication, or the importance of adherence.
Automated reminding—Participants in this condition participated in regular study visits
and assessments, but also received automated daily phone calls consisting of a recorded
message from the investigator reminding the participant to take their medication. The
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message consisted of a recording of the first author stating that he was calling the patient to
remind them to take their medication, either in Spanish or English.
The time of day that the message was programmed for delivery was determined at the time
of the second study visit (at which baseline adherence data were collected and participants
were randomized to one of the study conditions). The time was chosen based on patient
preference and the time of day at which they indicated that they usually took their
medication.
Tailored information—Participants in this condition at the second study visit received a
20-minute tailored information intervention that consisted of completing a questionnaire
about information they wanted to receive about memory disorders and their treatment.
Responses to the questionnaire, their preferred language, and their level of health literacy as
assessed by the Test of Functional Health Literacy in Adults (Parker, Baker, Williams, &
Nurss, 1995) were used as input to a computer program that then created a written response
tailored to participants’ language, level of health literacy, and requests for information. This
program, written in Visual Basic by the first author, allowed the investigator, also the first
author, to provide participants with individually-tailored information about memory
problems and aging, dementing illnesses, and their treatment. A list of topics consisting of
common issues that arise in clinical work with older individuals with memory problems was
first created by the first author. It was then reviewed by the director of the memory disorders
clinic, and a nurse with extensive experience in work with older adults.
During the study intervention, this list of topics was reviewed by the first author with the
participant and his or her caregiver. The participant indicated which topics were of interest
to them. These topics were then checked in the user interface of the computer program,
which then created a personalized information handout that included the participant’s name
and the date. In a separate procedure, a digital photograph of the participant was taken and
printed on a sheet that was inserted in a binder that also then included with the printout of
the requested information. The individually tailored information was then reviewed with the
participant and provided to him or her as a booklet for use at home. No other follow-up was
provided to this group other than the same procedures that all other participants completed.
Procedure
Participants were recruited during routine clinical visits at the memory disorders clinic or
from contact information available because they had participated in other research studies at
the clinic and randomized to one of the three conditions after written informed consent was
obtained. Participants were only included if they were judged to have the ability to provide
informed consent based on their understanding of the nature of the study and its
requirements. This determination was made by the first author during the informed consent
process after consideration of the participant’s understanding of key elements of informed
consent, such as the fact that they would participate in a research study, that their
participation was voluntary, and that declining to participate would not affect their future
treatment at the clinic. In cases in which participants came to study sessions with a
caregiver, the caregiver also was involved in the informed consent process.
At the initial study visit, participants completed a baseline battery of measures that included
assessments of cognitive status, mood, health literacy, self-efficacy, and health-related
quality of life. At this visit, they were also oriented to the use of the Medication Event
Monitoring System (MEMS; Aaprex, Union City, CA), the method used as the primary
measure of medication adherence. The system includes a pill bottle cap that records the date
and time of each opening. Recordings can be read into a computer on which software allows
the computation participants’ adherence. It calculates several measures of adherence based
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on when medications are taken in relation to the participants’ prescribed regimen. The index
used in this study is an index of the percentage of medication doses taken at appropriate
intervals (+/− 25% of the interval), sometimes called “timing adherence” (Grosset &
Grosset, 2007).
At this first visit, the battery of cognitive measures included the Alzheimer’s Disease
Assessment Scale, Cognitive subtest (ADAS-Cog; Rosen, Mohs, & Davis, 1984) in a form
that included the supplemental delayed recall, maze, and checking tasks (Mohs et al., 1997).
The battery also included the Hamilton Depression Rating Scale (Hamilton, 1960) and the
Test of Functional Health Literacy in Adults (Parker et al., 1995). Following completion of
the battery, participants were instructed in the use of the MEMS pill bottle, and their current
anticholinesterase medication was transferred to the MEMS pill bottle. At the second visit
one month later, participants’ baseline medication adherence was recorded, and they were
randomized to one of the three treatment conditions and followed at monthly intervals for
the first 12 months and at 3-month intervals for a second year. At monthly visits, the MEMS
cap was read into the computer, and participants were rated on the HAM-D. At quarterly
study visits (every three months), participants’ cognitive status was reassessed via
readministration of the ADAS-Cog with supplementary tests.
All assessment and intervention materials were available in both Spanish and English.
Spanish translations of assessment materials were already available. Tailored information
materials, including the questionnaire and educational materials, were first composed by the
first author in English and then translated by him into Spanish. Spanish translations were
then reviewed and corrected by an experienced bilingual clinician with extensive
background in memory disorders and general gerontology.
Data Analysis
Study hypotheses were evaluated using generalized estimating equation models. This
strategy was chosen in order to allow for the use of all available data while allowing for the
correlations among repeated measures over time. Timing adherence was used as the
dependent measure in the analyses presented here. Between-groups differences in baseline
adherence were assessed with the Kruskal-Wallis test.
Because of the non-normal distribution of our primary dependent variable (medication
adherence) and the longitudinal structure of our data, a generalized estimating equation
(GEE) model (Diggle, Liang, & Zeger, 1994) using Poisson regression with an independent
correlation structure and a log linking function was chosen to evaluate the effects of the
interventions while controlling for relevant potential confounders with repeated measures of
adherence over time. Covariates originally hypothesized to be related to adherence included
age, gender, language, general cognitive status, memory, mood, health literacy, and the
presence or absence of a caregiver.
Participants provided data at monthly visits after randomization. We evaluated the relation
of covariates including treatment group membership to these repeated measurements over
time using a GEE model that allowed for correction of observed errors using robust
(sandwich) estimators (Hardin & Hilbe, 2002). The form chosen for the correlation structure
of the GEE model was determined by evaluating alternative structures, including
autoregressive, unstructured, exchangeable, and independent, and choosing the form that
resulted in the smallest value of the quasi-likelihood information criterion (QIC) as
recommended by Hardin and Hilbe (2002). A full model was first estimated that included all
potentially relevant covariates. They were chosen based on demographic (age, gender,
language) considerations of previous research showing their effects on medication
adherence (cognitive variables and health literacy, mood, and presence or absence of a
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caregiver). All two-way interactions were included in a preliminary version of the full
model. This full model was reduced through successively eliminating nonsignificant
variables and then recalculating the model. Appropriateness of model changes was assessed
through changes in variable significance and review of the quasi-likelihood information
criterion corrected (QICC) also as recommended by Hardin and Hilbe (2002). The final
model thus included relevant demographic variables as well as significant predictors of
adherence.
RESULTS
Thirty participants were recruited for the study, all of whom contributed baseline cognitive
and health literacy data. Of these, 27 provided baseline adherence data at the second study
visit. These 27 were randomized to one of the treatment conditions. The three participants
who were recruited and who provided written informed consent but who did not continue in
the study each withdrew because of the time demands of the study. Twenty-four participants
were evaluated on at least two occasions and provided baseline and post-intervention data
for analysis in the models. These participants thus provided longitudinal data essential for
evaluating the effect of the interventions or the control condition over time.
Because of missing data for the depression and health literacy measures, the preliminary full
GEE model is based on only 23 participants. Of the 27 participants randomized, three
withdrew consent because of the time demands of the study, and one patient was lost to
follow-up after recruitment but before randomization after being hospitalized for a fall. Of
the 27 participants randomized, 16 were men and 11 were women. Fifteen participated in
English and 12 in Spanish; 15 had a primary caregiver who assisted with medication
adherence (in these cases the caregiver either reminded the participant or actually opened the
pill bottle for him or her) while 12 reported that they themselves assumed primary
responsibility for taking their medications. Eleven participants were assigned to the control
condition, 8 to automated reminding condition, and 8 to the tailored information condition.
There were no significant differences among the groups in primary language, gender, or
caregiver presence (all ps > .20). All patients had been prescribed donepezil (Aricept™),
either 5 or 10 mg, once per day for treatment of memory impairment. All participants had
been stable on their medications for at least 30 days at the time of their entry into the study.
Table 1 presents descriptive statistics for the continuous variables used in the study.
Categorical variables are summarized above. Groups did not differ significantly at baseline
in levels of adherence (Kruskal-Wallis χ2 = 2.20, p = .33).
Although specific diagnoses of mild cognitive impairment or Alzheimer’s disease were not
obtained as part of the study data collection, participants’ scores on the ADAS-Cog allow
characterization of the cognitive status of participants. The average total ADAS-Cog score
of the sample was 22.7 (SD = 11.4; range 5–59; higher scores indicate poorer performance),
and the average score on the supplemental delayed recall subtest was 7.9 (SD = 2.4; range
1–10). These scores are similar to those of persons diagnosed with either mild cognitive
impairment or mild Alzheimer’s disease in normative data reported by Pyo et al. (2006) who
showed that patients with a clinical diagnosis of Alzheimer’s disease and clear functional
impairment as evidenced by a score of 1 on the Clinical Dementia Rating Scale had an
average ADAS-Cog score of 15.72 (SD = 6.34). Current participants’ scores are also
consistent with a much poorer performance than normal elderly controls (mean age 72.1)
whose average score was 4.98 (SD = 2.25) (Graham, Cully, Snow, Massman, & Doody,
2004).
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Potential covariates for inclusion in GEE models were assessed with univariate tests of
between-group differences via one-way analysis of variance (ANOVA). Models were
developed based on demonstration of between-groups differences on covariates to be
included in the models as well as on conceptual relevance. Covariates evaluated included
age, gender, language, presence of a caregiver, and cognitive variables (general cognitive
status, delayed recall, executive function, and health literacy) as well as mood. The model
including all evaluated covariates is presented in Table 2. All two-way variable interactions
were evaluated as well in light of the small size of each group and the potential for between-
group differences that might affect results.
The model presented in Table 2 shows that language and gender were not related to
medication adherence after including age, the presence of a caregiver and verbal memory
(Delayed Recall) in the model. Measures of executive function (Mazes Time), health
literacy (TOFHLA), and depression (HAM-D) were also not related to adherence. Model-
corrected estimates of adherence are presented in Table 3, showing that both participants in
the Reminding and Tailored Information conditions had higher levels of adherence
compared to participants in the control group after taking relevant covariates into account.
As described above, nonsignificant effects in this full model were successively eliminated,
the model was recalculated, and model fit was again evaluated at each iteration. The final
model thus included general cognitive function (ADAS-Cog) and its interaction with group
membership. Demographic variables, even when nonsignificant, are included in the final
model due to their relevance. The reduced model is presented in Table 4. These data show
that age was no longer a significant predictor of adherence after taking other variables and
the interaction of group membership with general cognitive status into account. Data in
Table 5 present model-corrected group estimates of adherence. In the final model, corrected
estimates of each group’s adherence mirrored the general pattern seen in the full model with
both Reminding and Tailored Information groups showing higher levels of adherence than
control participants. The estimate for Tailored Information was significantly greater than for
control and Reminding participants.
DISCUSSION
The purpose of this study was to evaluate the effect of two interventions in improving
medication adherence in individuals treated for memory problems. Results suggest that both
of the interventions (automated telephone reminders or individually-tailored information)
may improve medication adherence. Perhaps due to our small sample size, estimates in each
model varied substantially, although both models produced results that suggested that both
interventions may be useful in improving medication adherence. In the full model that
included all possible covariates, both being older and having better long-term verbal
memory were associated with better adherence. When the model was reduced based on
evaluation of the significance of covariates and their interaction with group membership,
only the presence of a caregiver and long-term memory were positively associated with
better adherence.
These results highlight the role of caregivers in improving adherence in patients with
memory problems. Our findings are also consistent with previous studies that have shown
the importance of caregivers in adherence (Ben-Natan & Noselozich, 2011; Clark et al.,
2010; McCurry et al., 2010). We note that personal circumstances dictate whether or not a
patient seen in clinical practice has a caregiver who can assist with medications and that
both interventions appear to have had an additional effect on adherence even after taking the
presence of a caregiver into account.
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Increasing age was associated with improved medication adherence. This finding is
consistent with other studies that have shown that age, in itself, can be positively associated
with adherence (Park et al., 1999). However, the results of the latter study also show that
age-related declines in cognitive function may negatively influence adherence (Park et al.,
1999). Age may thus be related to better adherence in elders with preserved memory
function, but can itself be related to declines in memory functioning suggesting that an
understanding of the effects of age on adherence may depend on an understanding of an
individual’s cognitive status.
Similarly, the association of adherence with better long-term verbal memory is not
surprising, but emphasizes the role of basic cognitive skills in medication adherence
(Ownby, 2006). Other studies have suggested that complex abilities such as working
memory or executive skills may be related to medication adherence (Insel et al., 2006).
Although one might expect that general cognitive status (as measured with the total score on
the ADAS-Cog) and executive functions (as assessed by participants’ performance on a
maze solving task) would be related to adherence, we failed to find a relation. Given the
small sample size employed in this study, it is possible that we simply did not have adequate
statistical power to detect a relation that may have been present.
One purpose of this study was to evaluate the comparative effects of two distinct
interventions on medication adherence. This was a goal because several studies have shown
that interventions that combine several strategies may be effective in improving medication
adherence, but few studies have allowed an evaluation of the interventions’ distinct elements
in promoting adherence. Such studies do not allow a determination of whether any single
element of a combination strategy is by itself effective. This study suggests that both
automated reminding and tailored information may be useful in promoting medication
adherence. It is possible that a combination of the two strategies might have had additive
effects. It is also possible that one treatment might have been superior based on patients’
cognitive status. For example, automated reminding might be superior for patients without
caregivers who have memory and other cognitive deficits, while tailored information may be
helpful for patients with better cognitive function. It is possible that our small sample did not
provide us sufficient statistical power to detect these possible relations Future studies with
larger sample sizes may allow an evaluation of the ways in which the effectiveness of
different interventions may be related to patient characteristics.
Other researchers have also reported a relation between health literacy and adherence. We
did not find this relation, but again small sample size may have resulted in lower power to
detect the effect of this factor. It should also be noted that the tailored information
application adjusted for participants’ level of health literacy so that to an extent this factor
was incorporated in the study design. Persons in the automated reminding condition might
have been less affected by factors that required them to understand healthcare information,
so the impact of health literacy on adherence in both groups may have been reduced.
Whether health literacy might be related to medication adherence in other contexts is thus
not clear. Patients’ levels of health literacy may interact with how well they respond to
adherence interventions.
Our results thus show that tailored information and automated reminding may be useful
interventions to improve medication adherence in adults with memory problems. Although
researchers have shown that a variety of interventions can enhance medication adherence,
most of them are multifactorial and clinically intensive. The potential for computer-based
interventions to reduce the cost of implementing adherence interventions thus merits further
exploration.
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TABLE 2
Full Model Predicting Timing Adherence
Source χ2 df p
Intercept 352.39. 1 <.001
Language       .29 1   .59
Gender       .27 1   .61
Age     9.57 1   .002
Caregiver   13.20 1 <.001
Delayed recall     7.22 1   .007
ADAS-Cog       .05 1   .83
Mazes time       .005 1   .95
TOFHLA       .37 1   .54
HAM-D       .50 1   .48
Treatment group     5.37 2   .07
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TABLE 3
Estimated Marginal Means for Groups for the Full Model
95% Confidence interval
Group Mean Std. Error Lower Upper
Control 60.3 6.6 47.2 73.2
Reminding 75.7 5.5 65.0 86.5
Tailored information 78.6 3.4 70.9 84.2
Post-hoc tests (least significant difference); Control vs. Reminding, p = .02; Control vs. Tailored Information, p = .04; Reminding vs. Tailored
Information, p = .80.
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TABLE 4
Reduced Model
Source χ2 df p
Intercept 247.08 1 <.001
Gender     1.08 1   .30
Language       .07 1   .79
Age       .51 1   .47
Caregiver   14.82 1 <.001
Delayed recall     5.89 1   .02
ADAS-Cog       .21 1   .65
Treatment group X ADAS-Cog     7.12 2   .03
Treatment group   10.41 2   .005
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TABLE 5
Estimated Marginal Means for Groups for the Reduced Model
95% Wald Confidence
Interval
Group Mean SE Lower Upper
Control 60.0 6.1 48.1 72.0
Reminding 64.5 5.6 53.5 76.0
Tailored information 82.0 3.7 74.5 89.2
Post-hoc tests (least significant difference); Control vs. Reminding, p = .48; Control vs. Tailored Information, p = .004; Reminding vs. Tailored
Information = .03.
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